Bioxytran, Inc. is developing an innovative platform of oxygen treatments for hypoxic conditions, tissue ischemia, and necrosis prevention. In addition to stroke, trauma, and wound healing applications, the company is exploring how oxygen transport technology may support chronic kidney disease treatments where reduced oxygen delivery contributes to progressive tissue damage and declining kidney function.
Many chronic kidney disease stages are associated with renal hypoxia, inflammation, and impaired blood flow. Existing chronic kidney disease medication options primarily focus on slowing disease progression, managing blood pressure, reducing protein leakage, and controlling diabetes. However, oxygen deprivation within kidney tissue remains a significant challenge in advanced renal disease.
Traditional hyperbaric oxygen therapy has shown potential benefits in some hypoxic conditions, but treatment duration is limited because of oxygen toxicity concerns and free radical development. Hyperbaric chambers are also costly and restricted in accessibility. Bioxytran’s oxygen transport molecule is being designed to improve oxygen delivery while potentially reducing free radical formation associated with oxygen toxicity.
Oxygen is indispensable to the life of all human tissues, including the kidneys, brain, heart, and vascular system. Hemoglobin, a protein normally contained within red blood cells, carries and releases oxygen throughout the body. Under normal physiological conditions, approximately 98% of oxygen is transported by red blood cells, while the remaining oxygen is dissolved in plasma.
Many degenerative diseases, including chronic kidney disease, Alzheimer’s disease, dementia, and Parkinson’s disease, are linked to impaired tissue oxygenation and reduced blood flow. In chronic kidney disease, prolonged oxygen deprivation may contribute to fibrosis, inflammation, and progressive loss of kidney filtration capacity.
Bioxytran’s investigational oxygen transport platform, BXT-25, is designed to carry oxygen similarly to hemoglobin molecules found in red blood cells (RBCs). The company is evaluating how this oxygen therapeutic approach may support hypoxic tissues in multiple disease indications, including future areas related to chronic kidney disease treatments and renal ischemia.
Oxygen is essential for neuronal communication, brain development, energy metabolism, and tissue survival. Hemoglobin, a protein normally found within red blood cells, carries and releases oxygen throughout the body. Under normal physiological conditions, most oxygen is transported through red blood cells, while a smaller percentage remains dissolved within plasma.
Many neurological and degenerative diseases, including autism spectrum disorder, Alzheimer’s disease, dementia, Parkinson’s disease, and stroke-related injury, are increasingly being studied in connection with inflammation, impaired oxygen utilization, oxidative stress, and altered microvascular circulation.
Researchers are evaluating whether chronic neuroinflammation and tissue hypoxia may contribute to neurological dysfunction, altered synaptic signaling, and cellular stress within the developing brain.
Bioxytran’s investigational oxygen transport platform, BXT-25, is designed to transport oxygen similarly to hemoglobin molecules found in red blood cells (RBCs). The company is evaluating how this oxygen therapeutic approach may support hypoxic tissues in multiple neurological and inflammatory disease pathways involving impaired oxygen delivery and tissue stress.
Chronic kidney disease occurs when the kidneys gradually lose their ability to filter toxins, regulate fluids, and maintain electrolyte balance. As chronic kidney disease stages progress, reduced oxygen supply to kidney tissue may accelerate inflammation, nephron damage, and tissue scarring.
Current CKD treatments often combine patient-led lifestyle changes with medical interventions, including blood pressure management, diabetes control, chronic kidney disease medication regimens, dialysis support, and kidney transplantation in advanced disease. However, many patients continue to experience a gradual decline in kidney function over time.
Bioxytran’s lead drug candidate, BXT-25, is an investigational oxygen transport therapy intended to support tissue oxygenation during ischemic and hypoxic events. The platform is being explored as a chronic kidney disease injectable therapeutic approach for conditions where oxygen delivery becomes compromised.
The small synthetic molecule is designed to transport oxygen efficiently through circulation and release oxygen directly into oxygen-deprived tissues. By improving tissue oxygenation, the platform may potentially help support cellular function in ischemic and inflammatory environments.
The BXT-25 molecule contains a co-polymer designed to stabilize cross-linked hemoglobin subunits as a universal oxygen carrier. BXT-25 is administered as an injectable IV solution whose molecules are approximately 5,000 times smaller than red blood cells. This allows the molecule to circulate through narrowed or partially obstructed microvascular pathways where oxygen delivery may otherwise become impaired.
The oxygen is delivered rapidly upon infusion, and the molecule is designed to mimic the oxygen affinity of natural human red blood cells. BXT-25 is also designed to be non-immunogenic and universally compatible across blood types.
Chronic kidney disease stages are categorized based on glomerular filtration rate (GFR), which measures how efficiently the kidneys filter blood.
Early kidney damage with mild reduction in kidney function. Patients may not experience noticeable symptoms.
Moderate decline in kidney function. Fatigue, swelling, blood pressure changes, and abnormal lab findings may begin to appear.
Severe reduction in kidney function with increasing risk of complications, including anemia, cardiovascular disease, and fluid retention.
Kidney failure requiring dialysis, transplant support, or advanced renal care management.
Progressive hypoxia and reduced microvascular oxygen delivery are believed to contribute to worsening kidney tissue injury across all chronic kidney disease stages.
Current chronic kidney disease medication options may include:
Advanced chronic kidney disease injectable therapies are increasingly being explored to address inflammation, fibrosis, and oxygen deprivation in kidney tissue.
Bioxytran’s oxygen transport platform represents a different investigational approach focused on tissue oxygenation rather than solely symptom management.
Ischemic conditions occur when blood flow and oxygen delivery to tissues become restricted. In chronic kidney disease, reduced circulation within the renal microvasculature may contribute to chronic tissue hypoxia and long-term kidney damage.
The small molecular size of BXT-25 may allow oxygen transport through partially obstructed vascular pathways where traditional red blood cells may have difficulty circulating efficiently. This investigational mechanism is being explored across ischemic conditions involving restricted oxygen delivery.
Inadequate tissue oxygenation may contribute to:
Traditional red blood cell transfusions may not effectively address oxygen delivery in highly restricted microvascular environments because of cell size limitations.
Hemorrhagic conditions involve blood vessel rupture and tissue injury that impair oxygen delivery and circulation. BXT-25 is designed as a stable injectable oxygen therapeutic with potential applications in emergency and critical care environments.
Due to its stability profile, the platform may support future rapid deployment injectable therapeutic applications in acute ischemic and hypoxic conditions.
The company is also evaluating broader oxygen therapeutic opportunities where inflammation, vascular compromise, and tissue hypoxia contribute to disease progression.
Many degenerative and chronic diseases are associated with impaired oxygen delivery, inflammation, and cellular stress. Future research areas being explored include:
Chronic kidney disease remains an area of growing interest because hypoxia is increasingly recognized as a contributing factor in progressive kidney injury and declining renal function.
Through its investigational oxygen transport platform, Bioxytran, Inc. continues to explore new approaches aimed at improving tissue oxygenation and supporting future innovation in chronic kidney disease treatments and injectable oxygen therapeutics.
CKD is a condition where the kidneys slowly start to lose the ability to filter waste and fluids from the blood
Typical drivers are diabetes, high blood pressure, reduced blood flow, inflammation, and damage to kidney tissue
BXT-25 is Bioxytran’s investigational oxygen transport, injectable therapy, meant to help oxygen reach hypoxic tissues better
When oxygen delivery drops, it can help fuel kidney inflammation, scarring, and a gradual decline in kidney function, over time
CKD moves from Stage 1 (mild damage) up to Stage 5, which is also known as end-stage renal disease (ESRD)
